Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects

AstraZeneca

Status and phase: Completed; Phase 4

Conditions: Healthy

Treatments: Drug: Nexium; Drug: Prevacid

Study type: Interventional

Funder types: Industry

Identifiers

NCT00230516

D9612L00080

Details and patient eligibility

About

This study is intended to evaluate whether intravenous (iv) esomeprazole (Nexium® ) offers better intragastric acid suppression than iv lansoprazole (Prevacid ®

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Participants must be 18-70 years of age
• Participants can be male or female
• Women that are able to have children must have a negative pregnancy test.

Exclusion criteria

• Involvement in or planning of this study
• Participation in another clinical study within 28 days of this one
• For women, pregnancy or attempting to become pregnant.